A Randomized Trial of Five Cisplatin-Containing Treatments in Patients With Metastatic Non-Small-Cell Lung Cancer: A Southwest Oncology Group Study

Six hundred eighty assessable patients with measur-able stage III M1 non-small-cell lung cancer (NSCLC) were randomized to one of five treatment arms includ-ing cisplatin, etoposide (VP-16) + methylglyoxal bis-guanylhydrazone (MGBG; PVp, PVpM); cisplatin, vin-blastine (PVe); or PVe alternating with vinblastine, mitomycin (PVeMi); or fluorouracil, vincristine, mitomy-cin/cyclophosphamide, doxorubicin, cisplatin (FOMi/ CAP). The overall response rate was 20 % with 3% complete responses and 17 % partial remissions. The duration of these responses was not statistically dif-T HE SOUTHWEST Oncology Group (SWOG) in 1982 completed a trial of chemotherapy in extensive non-small-cell lung cancer (NSCLC), which indicated that an alternating combination o